North America Non Hodgkin Lymphoma Diagnostics Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2024 –2030 |
 Market Size (Base Year) |
|
 Market Size (Forecast Year) |
|
 CAGR |
% |
| Major Markets Players |
北美非霍奇金淋巴瘤诊断市场，按测试类型（成像、活检、免疫组织化学、生物标志物、基因测试、细胞遗传学、腰椎穿刺、血液测试、细胞化学等）、癌症分期（IV 期、III 期、II 期、I 期和 0 期）、肿瘤类型（侵袭性淋巴瘤和惰性淋巴瘤）、产品（基于仪器的产品、基于平台的产品、试剂盒和试剂及其他消耗品）、技术（荧光原位杂交、下一代测序、荧光免疫测定、比较基因组杂交、免疫组织化学等）、应用（筛查、诊断和预测、预后和研究）、最终用户（医院、诊断中心、癌症研究中心、学术机构、门诊手术中心等）、分销渠道（直接招标、零售等）- 行业2030 年的趋势和预测。
北美非霍奇金淋巴瘤诊断市场分析与洞察
北美对非霍奇金淋巴瘤的认识不断提高，增强了市场需求。为获得更好的医疗服务而增加的医疗支出也促进了市场的增长。在这一关键时期，主要市场参与者专注于各种服务的推出和批准。此外，诊断过程和技术的改进也促进了对非霍奇金淋巴瘤诊断测试的需求增加。
由于市场参与者的增加和先进服务的可用性，北美非霍奇金淋巴瘤诊断市场预计将在预测年内增长。与此同时，制造商正致力于研发活动，以在市场上推出新服务。非霍奇金淋巴瘤诊断和开发领域的研究不断增加，进一步推动了市场的增长。然而，非霍奇金淋巴瘤筛查技术的困难可能会阻碍预测期内北美非霍奇金淋巴瘤诊断市场的增长。
预计癌症诊断和治疗方面的医疗支出增加将为市场提供提升治疗水平的机会。然而，检测成本高昂，且癌症诊断产品审批和商业化的法规和标准严格，可能会对市场增长构成挑战。
北美非霍奇金淋巴瘤诊断市场具有支持性，旨在减缓疾病的进展。Data Bridge Market Research 分析称，在 2023 年至 2030 年的预测期内，北美非霍奇金淋巴瘤诊断市场将以 9.1% 的复合年增长率增长。
|
报告指标 |
细节 |
|
预测期 |
2023 至 2030 年 |
|
基准年 |
2022 |
|
历史岁月 |
2021（可定制为 2015 - 2020） |
|
定量单位 |
收入（百万美元）和定价（美元） |
|
涵盖的领域 |
测试类型（成像、活检、免疫组织化学、生物标志物、基因测试、细胞遗传学、腰椎穿刺、血液测试、细胞化学等）、癌症分期（IV 期、III 期、II 期、I 期和 0 期）、肿瘤类型（侵袭性淋巴瘤和惰性淋巴瘤）、产品（基于仪器的产品、基于平台的产品、试剂盒和试剂以及其他耗材）、技术（荧光原位杂交、下一代测序、荧光免疫测定、比较基因组杂交、免疫组织化学等）、应用（筛查、诊断和预测、预后和研究）、最终用户（医院、诊断中心、癌症研究中心、学术机构、门诊手术中心等）、分销渠道（直接招标、零售等） |
|
覆盖国家 |
美国、加拿大、墨西哥 |
|
涵盖的市场参与者 |
佳能医疗系统株式会社（日本枥木县）、荷兰皇家飞利浦公司（荷兰阿姆斯特丹）、西门子医疗有限公司（德国埃尔朗根）、丹纳赫公司（美国华盛顿州）、Bio-Rad Laboratories, Inc（美国加利福尼亚州）、通用电气公司（美国马萨诸塞州）、Sysmex Corporation（日本兵库县）、Grail（美国加利福尼亚州）、F. Hoffmann-La Roche（瑞士巴塞尔）、东软集团（中国沈阳）、安捷伦科技公司（美国加利福尼亚州）、NeoGenomics Laboratories（美国佛罗里达州）、Hologic, Inc（美国马萨诸塞州）、Integrated DNA Technologies, Inc.、CENTOGENE NV（德国罗斯托克）、Merit Medical Systems（美国犹他州）、Invitae Corporation（美国加利福尼亚州）、PerkinElmer Inc.（美国马萨诸塞州）、QIAGEN （美国加利福尼亚州）以及 GeneDx, LLC（美国康涅狄格州）等。 |
市场定义
癌症始于淋巴，最常发生在吸烟者身上。非霍奇金淋巴瘤有两种主要类型：侵袭性非霍奇金淋巴瘤和惰性非霍奇金淋巴瘤。非霍奇金淋巴瘤的病因包括吸烟、二手烟、接触某些毒素和家族病史。
症状包括咳嗽（通常带血）、胸痛、喘息和体重减轻。这些症状通常在癌症晚期才会出现。治疗方法多种多样，但可能包括手术、化疗、放射治疗、靶向药物治疗和免疫治疗。
北美非霍奇金淋巴瘤诊断市场动态
本节旨在了解市场驱动因素、优势、机遇、限制和挑战。以下内容将详细讨论所有这些内容：
- 非霍奇金淋巴瘤患病率增长
淋巴瘤是许多相关癌症亚型的统称，这些癌症源自一种名为“淋巴细胞”的白细胞。淋巴瘤分为两大类：霍奇金淋巴瘤 (HL) 和非霍奇金淋巴瘤 (NHL)。非霍奇金淋巴瘤是淋巴瘤的一个大类。有许多亚型属于这一类。弥漫性大 B 细胞淋巴瘤和滤泡性淋巴瘤是最常见的亚型。淋巴瘤癌症病例在世界各地呈上升趋势。非霍奇金淋巴瘤 (NHL) 是美国最常见的癌症之一，约占所有癌症的 4%。
男性一生中患上 NHL 的几率约为 1/43；而女性患上 NHL 的几率约为 1/53。2020 年，根据世界卫生组织 (WHO) 国际癌症研究机构的数据，全球约有 544,352 人被诊断患有非霍奇金淋巴瘤。
- 提高对非霍奇金淋巴瘤的认识
非霍奇金淋巴瘤宣传活动是提高人们对这些疾病的认识并关注其病因、预防、诊断、治疗和生存研究的机会。目的是帮助受淋巴瘤影响的人并促进健康的习惯。
全球第五大癌症是淋巴瘤，根据世界卫生组织的报告，亚洲是发病率最高的地区，过去5年共有241,270名患者，非霍奇金淋巴瘤占亚洲所有癌症死亡人数的7.4%，死亡率每年都在缓慢上升。
每年，世界各地都会举办多场宣传活动、网络研讨会和会议，向人们普及非霍奇金淋巴瘤知识，各组织也在这些活动中发挥带头作用。因此，这有望推动北美非霍奇金淋巴瘤诊断市场的增长。
- 缺乏训练有素、技术娴熟的医疗专业人员
卫生人员总数的密度估计为每 10,000 人口 29 人，但每 10,000 人中只有 16 人是经过培训的工作人员。对熟练和认证的专业人员的需求是北美非霍奇金淋巴瘤诊断市场的一大制约因素。由于癌症和遗传异常病例的增加，对荧光原位杂交的需求增加，但熟练专业人员数量较少预计将阻碍市场的增长。
合格的执业医师进行多项测试的能力对于医疗保健和医疗行业的发展至关重要。拥有专业团队的主要目标是确保每件救生医疗设备在最需要时都能有效发挥作用。技术人员需要接受相关制造商和机构的适当教育和认证。
技术人员面临技术培训方面的缺口，这些缺口与如何安全地采用先进方法高效执行程序有关。对于淋巴瘤的诊断，需要大量熟练的专业人员进行方法开发、验证、操作和故障排除活动
- 针对不同治疗和诊断的严格规定和指南
在这些司法管辖区销售医疗器械或药品可能需要大量的财务支出，而且可能需要数月或数年才能完成。如果不了解或考虑这些限制，延误可能会严重危及在竞争激烈的市场中取得成功的可能性。但它们在全球多个地区的批准和营销需要满足严格的监管标准并获得各监管机构的认可。
公司必须仔细审查产品规格，然后根据美国食品药品管理局 (FDA) 的规定对产品进行分类。在学术、非营利和其他生命科学研究公司中设立药物发现和开发项目需要仔细规划。每个国家都有自己的监管机构，监管机构对药物发现研究的监督很少，但提供了某些要求和明确的文件，以在此过程中实现里程碑。监管框架旨在改善获得更高质量产品的渠道，并为加强监管控制提供指导。
COVID-19 对北美非霍奇金淋巴瘤诊断市场的影响
COVID-19 给全球卫生保健系统带来了沉重负担，这引起了肿瘤内科医生对 COVID-19 对非霍奇金淋巴瘤诊断和治疗影响的担忧。我们在这项回顾性队列研究中调查了 COVID-19 时代之前和之后 COVID-19 对非霍奇金淋巴瘤诊断和治疗的影响。在大流行期间，新诊断的非霍奇金淋巴瘤数量减少，疾病的阶段略有增加，与 COVID-19 之前相比，放射外科手术作为第一种确定性治疗的比例显著增加，全身治疗和手术的比例均有所下降。与 COVID-19 之前相比，大流行期间开始化疗和放射治疗没有明显延迟。
然而，在疫情期间，我们观察到非霍奇金淋巴瘤手术有所延迟。COVID-19 似乎对我们非霍奇金淋巴瘤中心的非霍奇金淋巴瘤患者的诊断和治疗模式产生了重大影响。许多肿瘤学家担心，未来一年新诊断的非霍奇金淋巴瘤患者的数量将会增加。这项研究仍在进行中，我们将收集和分析更多信息，以更好地了解 COVID-19 疫情对我们的非霍奇金淋巴瘤患者群体的总体影响。
近期发展
- 2022 年 11 月，丹纳赫宣布与杜克大学建立战略合作伙伴关系，成立首个丹纳赫基因治疗创新灯塔项目。该项目投资于产品创新，以推进外部研发战略，重点关注基因组药物、精准诊断、下一代生物制造、人体系统和数据科学。
- 2022 年 8 月，Bio-Rad Laboratories Inc. 收购了 Curiosity Diagnostics，这是一家总部位于波兰的医疗诊断和医疗保健市场创新技术解决方案开发商。此举帮助该公司扩大了其产品组合和北美市场占有率。
北美非霍奇金淋巴瘤诊断市场细分
北美非霍奇金淋巴瘤诊断市场分为八个显著的细分市场，根据检测类型、癌症分期、肿瘤类型、产品、技术、应用、最终用户和分销渠道划分。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。
按测试类型
- 影像学
- 活检
- 免疫组织化学
- 生物标志物测试
- 基因检测
- 细胞遗传学
- 腰椎穿刺（脊椎穿刺）
- 验血
- 细胞化学
- 其他的
根据癌症分期
- 第 0 阶段
- 第一阶段
- 第二阶段
- 第三阶段
- 第四阶段
按肿瘤类型
- 侵袭性淋巴瘤
- 惰性淋巴瘤
按产品
- 基于仪器的产品
- 基于平台的产品
- 试剂盒和试剂
- 其他耗材
按技术分类
- 荧光原位杂交
- 下一代测序
- 荧光免疫分析法
- 比较基因组杂交
- 免疫组织化学
- 其他的
按应用
- 筛查
- 诊断和预测
- 预测
- 研究
由最终用户
- 医院
- 诊断中心
- 癌症研究中心
- 学术机构
- 门诊手术中心
- 其他的
按分销渠道
- 直接招标
- 零售销售
- 其他的
北美非霍奇金淋巴瘤诊断市场区域分析/见解
对北美非霍奇金淋巴瘤诊断市场进行了分析，并按上述测试类型、癌症阶段、肿瘤类型、产品、技术、应用、最终用户、分销渠道提供了市场规模洞察和趋势。
非霍奇金淋巴瘤诊断报告涵盖的国家包括美国、加拿大、墨西哥、
美国在北美非霍奇金淋巴瘤诊断市场占据主导地位。非霍奇金淋巴瘤诊断和发展领域的研究不断增加，进一步推动了北美市场的增长。美国在北美地区占据主导地位，因为该国对癌症诊断和咨询服务的认识呈指数级增长。
报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和市场监管变化。下游和上游价值链分析、技术趋势和波特五力分析以及案例研究等数据点是用于预测各个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了北美品牌的存在和可用性以及由于来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。
竞争格局和北美非霍奇金淋巴瘤诊断市场份额分析
北美非霍奇金淋巴瘤诊断市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、北美业务、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度以及应用主导地位。以上提供的数据点仅与公司对非霍奇金淋巴瘤诊断市场的关注有关。
市场上的一些主要参与者包括佳能医疗系统公司、荷兰皇家飞利浦公司、西门子医疗有限公司、丹纳赫、Bio-Rad Laboratories, Inc.、通用电气公司、Sysmex Corporation、Grail、F. Hoffmann-La Roche、东软集团、安捷伦科技公司、NeoGenomics Laboratories、Hologic, Inc、Integrated DNA Technologies, Inc.、CENTOGENE NV、Merit Medical Systems、Invitae Corporation、PerkinElmer Inc.、QIAGEN 和 GeneDx, LLC 等。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER'S 5 FORCES
5 INDUSTRY INSIGHTS
6 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, REGULATIONS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASED GROWTH IN PREVALENCE OF NON-HODGKIN LYMPHOMA
7.1.2 INCREASE IN AWARENESS REGARDING NON-HODGKIN LYMPHOMA
7.1.3 ADVANCEMENT IN ARTIFICIAL INTELLIGENCE IN DIAGNOSIS OF NON-HODGKIN LYMPHOMA
7.1.4 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UP
7.2 RESTRAINTS
7.2.1 LACK OF AVAILABILITY OF TRAINED AND SKILLED MEDICAL PROFESSIONALS
7.2.2 STRINGENT REGULATIONS AND GUIDELINES FOR DIFFERENT TREATMENTS AND DIAGNOSIS
7.3 OPPORTUNITIES
7.3.1 TECHNICAL ADVANCEMENTS IN CANCER DIAGNOSIS
7.3.2 INCREASING HEALTHCARE EXPENDITURE IN CANCER R&D
7.3.3 GROWING INITIATIVES BY GOVERNMENT AND KEY PLAYERS
7.4 CHALLENGES
7.4.1 LACK OF EARLY DIAGNOSTIC AWARENESS AMONG PEOPLE
7.4.2 HIGH DIAGNOSTIC COST AND FEAR OF TREATMENT
7.4.3 COMMON MISDIAGNOSIS OF NON-HODGKIN LYMPHOMA (NHL)
8 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY TEST TYPE
8.1 OVERVIEW
8.2 IMAGING
8.2.1 COMPUTED TOMOGRAPHY (CT)
8.2.2 CHEST X-RAY
8.2.3 MAGNETIC RESONANCE IMAGING (MRI)
8.2.4 ULTRASOUND
8.2.5 POSITRON EMISSION TOMOGRAPHY (PET)
8.3 BIOPSY
8.3.1 EXCISIONAL OR INCISIONAL BIOPSY
8.3.2 CORE NEEDLE BIOPSY
8.4 IMMUNOHISTOCHEMISTRY
8.5 BIOMARKER TEST
8.5.1 BETA 2-M
8.5.2 LDH
8.5.3 CA-125
8.5.4 TP53
8.5.5 NPM1
8.5.6 OTHERS
8.6 GENETIC TEST
8.7 CYTOGENETICS
8.8 LUMBAR PUNCTURE (SPINAL TAP)
8.9 BLOOD TEST
8.1 CYTOCHEMISTRY
8.11 OTHERS
9 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY TUMOR TYPE
9.1 OVERVIEW
9.2 AGGRESSIVE LYMPHOMAS
9.2.1 DIFFUSE LARGE B CELL LYMPHOMA
9.2.1.1 INSTRUMENT BASED PRODUCTS
9.2.1.2 PLATFORM BASED PRODUCTS
9.2.1.3 KITS AND REAGENTS
9.2.1.4 OTHER CONSUMABLES
9.2.2 ANAPLASTIC LARGE-CELL LYMPHOMA
9.2.2.1 INSTRUMENT BASED PRODUCTS
9.2.2.2 PLATFORM BASED PRODUCTS
9.2.2.3 KITS AND REAGENTS
9.2.2.4 OTHER CONSUMABLES
9.2.3 MANTLE CELL LYMPHOMA
9.2.3.1 INSTRUMENT BASED PRODUCTS
9.2.3.2 PLATFORM BASED PRODUCTS
9.2.3.3 KITS AND REAGENTS
9.2.3.4 OTHER CONSUMABLES
9.2.4 PERIPHERAL T-CELL LYMPHOMA
9.2.4.1 INSTRUMENT BASED PRODUCTS
9.2.4.2 PLATFORM BASED PRODUCTS
9.2.4.3 KITS AND REAGENTS
9.2.4.4 OTHER CONSUMABLES
9.2.5 LYMPHOBLASTIC LYMPHOMA
9.2.5.1 INSTRUMENT BASED PRODUCTS
9.2.5.2 PLATFORM BASED PRODUCTS
9.2.5.3 KITS AND REAGENTS
9.2.5.4 OTHER CONSUMABLES
9.2.6 BURKITT LYMPHOMA
9.2.6.1 INSTRUMENT BASED PRODUCTS
9.2.6.2 PLATFORM BASED PRODUCTS
9.2.6.3 KITS AND REAGENTS
9.2.6.4 OTHER CONSUMABLES
9.3 INDOLENT LYMPHOMAS
9.3.1 FOLLICULAR LYMPHOMA
9.3.1.1 INSTRUMENT BASED PRODUCTS
9.3.1.2 PLATFORM BASED PRODUCTS
9.3.1.3 KITS AND REAGENTS
9.3.1.4 OTHER CONSUMABLES
9.3.2 CUTANEOUS T-CELL LYMPHOMA
9.3.2.1 INSTRUMENT BASED PRODUCTS
9.3.2.2 PLATFORM BASED PRODUCTS
9.3.2.3 KITS AND REAGENTS
9.3.2.4 OTHER CONSUMABLES
9.3.3 MARGINAL ZONE B CELL LYMPHOMA
9.3.3.1 INSTRUMENT BASED PRODUCTS
9.3.3.2 PLATFORM BASED PRODUCTS
9.3.3.3 KITS AND REAGENTS
9.3.3.4 OTHER CONSUMABLES
9.3.4 LYMPHOPLASMACYTIC LYMPHOMA
9.3.4.1 INSTRUMENT BASED PRODUCTS
9.3.4.2 PLATFORM BASED PRODUCTS
9.3.4.3 KITS AND REAGENTS
9.3.4.4 OTHER CONSUMABLES
9.3.5 SMALL-CELL LYMPHOCYTIC LYMPHOMA
9.3.5.1 INSTRUMENT BASED PRODUCTS
9.3.5.2 PLATFORM BASED PRODUCTS
9.3.5.3 KITS AND REAGENTS
9.3.5.4 OTHER CONSUMABLES
10 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY APPLICATION
10.1 OVERVIEW
10.2 SCREENING
10.2.1 INSTRUMENT BASED PRODUCTS
10.2.2 PLATFORM BASED PRODUCTS
10.2.3 KITS AND REAGENTS
10.2.4 OTHER CONSUMABLES
10.3 DIAGNOSTIC AND PREDICTIVE
10.3.1 INSTRUMENT BASED PRODUCTS
10.3.2 PLATFORM BASED PRODUCTS
10.3.3 KITS AND REAGENTS
10.3.4 OTHER CONSUMABLES
10.4 PROGNOSTIC
10.4.1 INSTRUMENT BASED PRODUCTS
10.4.2 PLATFORM BASED PRODUCTS
10.4.3 KITS AND REAGENTS
10.4.4 OTHER CONSUMABLES
10.5 RESEARCH
10.5.1 INSTRUMENT BASED PRODUCTS
10.5.2 PLATFORM BASED PRODUCTS
10.5.3 KITS AND REAGENTS
10.5.4 OTHER CONSUMABLES
11 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE
11.1 OVERVIEW
11.2 STAGE IV
11.3 STAGE I
11.4 STAGE III
11.5 STAGE II
11.6 STAGE 0
12 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY TECHNOLOGY
12.1 OVERVIEW
12.2 FLUORESCENT IN SITU HYBRIDIZATION
12.3 NEXT GENERATION SEQUENCING
12.4 FLUORIMMUNOASSAY
12.5 COMPARATIVE GENOMIC HYBRIDIZATION
12.6 IMMUNOHISTOLOCHEMICAL
12.7 OTHER
13 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY PRODUCT
13.1 OVERVIEW
13.2 INSTRUMENT BASED PRODUCTS
13.2.1 IMAGING
13.2.2 BIOPSY
13.3 PLATFORM BASED PRODUCTS
13.3.1 NEXT-GENERATION SEQUENCING
13.3.2 MICROARRAYS
13.3.3 PCR
13.3.4 OTHERS
13.4 KITS AND REAGENTS
13.4.1 NON-HODGKIN LYMPHOMA PANELS
13.4.2 IMMUNOHISTOCHEMISTRY STAINS
13.4.3 OTHERS
13.5 OTHER CONSUMABLES
14 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 DIAGNOSTIC CENTERS
14.4 CANCER RESEARCH CENTERS
14.5 ACADEMIC INSTITUTES
14.6 AMBULATORY SURGICAL CENTERS
14.7 OTHERS
15 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 DIRECT TENDER
15.3 RETAIL SALES
15.4 OTHERS
16 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION
16.1 NORTH AMERICA
16.1.1 U.S.
16.1.2 CANADA
16.1.3 MEXICO
17 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
18 SWOT ANALYSIS
19 NORTH AMERICA NON-HODKIN LYMPHOMA DIAGNOSTICS MARKET
19.1 CANON MEDICAL SYSTEMS CORPORATION
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENT
19.2 KONINKLIJKE PHILIPS N.V.
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENTS
19.3 SIEMENS HEALTHCARE GMBH
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENT
19.4 DANAHER.
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENTS
19.5 BIO-RAD LABORATORIES, INC.
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 COMPANY SHARE ANALYSIS
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPMENT
19.6 AGILENT TECHNOLOGIES, INC.
19.6.1 COMPANY PROFILE
19.6.2 REVENUE ANALYSIS
19.6.3 PRODUCT PORTFOLIO
19.6.4 RECENT DEVELOPMENT
19.7 CENTOGENE N.V.
19.7.1 COMPANY SNAPSHOT
19.7.2 PRODUCT PORTFOLIO
19.7.3 RECENT DEVELOPMENT
19.8 F. HOFFMANN- LA ROCHE LTD
19.8.1 COMPANY SNAPSHOT
19.8.2 REVENUE ANALYSIS
19.8.3 PRODUCT PORTFOLIO
19.8.4 RECENT DEVELOPMENTS
19.9 GENERAL ELECTRIC COMPANY
19.9.1 COMPANY SNAPSHOT
19.9.2 REVENUE ANALYSIS
19.9.3 PRODUCT PORTFOLIO
19.9.4 RECENT DEVELOPMENTS
19.1 GENEDX, LLC
19.10.1 COMPANY SNAPSHOT
19.10.2 PRODUCT PORTFOLIO
19.10.3 RECENT DEVELOPMENT
19.11 GRAIL
19.11.1 COMPANY PROFILE
19.11.2 PRODUCT PORTFOLIO
19.11.3 RECENT DEVELOPMENT
19.12 HOLOGIC INC.
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 PRODUCT PORTFOLIO
19.12.4 RECENT DEVELOPMENT
19.13 INVITAE CORPORATION
19.13.1 COMPANY PROFILE
19.13.2 REVENUE ANALYSIS
19.13.3 PRODUCT PORTFOLIO
19.13.4 RECENT DEVELOPMENT
19.14 NEUSOFT CORPORATION
19.14.1 COMPANY SNAPSHOT
19.14.2 REVENUE ANALYSIS
19.14.3 PRODUCT PORTFOLIO
19.14.4 RECENT DEVELOPMENT
19.15 NEOGENOMICS LABORATORIES
19.15.1 COMPANY SNAPSHOT
19.15.2 REVENUE ANALYSIS
19.15.3 PRODUCT PORTFOLIO
19.15.4 RECENT DEVELOPMENTS
19.16 PERKINELMER INC
19.16.1 COMPANY PROFILE
19.16.2 REVENUE ANALYSIS
19.16.3 PRODUCT PORTFOLIO
19.16.4 RECENT DEVELOPMENT
19.17 QIAGEN
19.17.1 COMPANY SNAPSHOT
19.17.2 REVENUE ANALYSIS
19.17.3 PRODUCT PORTFOLIO
19.17.4 RECENT DEVELOPMENT
19.18 SYSMEX CORPORATION
19.18.1 COMPANY SNAPSHOT
19.18.2 REVENUE ANALYSIS
19.18.3 PRODUCT PORTFOLIO
19.18.4 RECENT DEVELOPMENTS
20 QUESTIONNAIRE
21 RELATED REPORTS
表格列表
TABLE 1 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 2 NORTH AMERICA IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 3 NORTH AMERICA IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 4 NORTH AMERICA BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 5 NORTH AMERICA BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 6 NORTH AMERICA IMMUNOHISTOCHEMISTRY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 7 NORTH AMERICA BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 8 NORTH AMERICA BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 9 NORTH AMERICA GENETIC TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 10 NORTH AMERICA CYTOGENETICS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 11 NORTH AMERICA LUMBAR PUNCTURE (SPINAL TAP) IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 12 NORTH AMERICA BLOOD TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 13 NORTH AMERICA CYTOCHEMISTRY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 NORTH AMERICA OTHERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 15 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 16 NORTH AMERICA AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 17 NORTH AMERICA AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 18 NORTH AMERICA DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 19 NORTH AMERICA ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 20 NORTH AMERICA MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 21 NORTH AMERICA PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 22 NORTH AMERICA LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 23 NORTH AMERICA BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 24 NORTH AMERICA INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 25 NORTH AMERICA AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 26 NORTH AMERICA FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 27 NORTH AMERICA CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 28 NORTH AMERICA MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 29 NORTH AMERICA LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 30 NORTH AMERICA SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 31 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 32 NORTH AMERICA SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 33 NORTH AMERICA SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 34 NORTH AMERICA DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 35 NORTH AMERICA DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 36 NORTH AMERICA PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 37 NORTH AMERICA PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 38 NORTH AMERICA RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 39 NORTH AMERICA RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 40 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 41 NORTH AMERICA STAGE IV IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 42 NORTH AMERICA STAGE I IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 43 NORTH AMERICA STAGE III IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 44 NORTH AMERICA STAGE II IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION
TABLE 45 NORTH AMERICA STAGE 0 IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 46 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 47 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 48 NORTH AMERICA NEXT GENERATION SEQUENCING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 49 NORTH AMERICA FLUORIMMUNOASSAY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 50 NORTH AMERICA COMPARATIVE GENOMIC HYBRIDIZATION IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 51 NORTH AMERICA IMMUNOHISTOCHEMICAL IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 52 NORTH AMERICA OTHERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 53 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 54 NORTH AMERICA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 55 NORTH AMERICA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 56 NORTH AMERICA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 57 NORTH AMERICA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 58 NORTH AMERICA KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 59 NORTH AMERICA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 60 NORTH AMERICA OTHER CONSUMABLES IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION))
TABLE 61 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 62 NORTH AMERICA HOSPITALS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 63 NORTH AMERICA DIAGNOSTIC CENTERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 64 NORTH AMERICA CANCER RESEARCH CENTERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 65 NORTH AMERICA ACADEMIC INSTITUTES IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 66 NORTH AMERICA AMBULATORY SURGICAL CENTERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 67 NORTH AMERICA OTHERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 68 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 69 NORTH AMERICA DIRECT TENDER IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 70 NORTH AMERICA RETAIL SALES IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 71 NORTH AMERICA OTHERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 72 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 73 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 74 NORTH AMERICA IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 75 NORTH AMERICA BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 76 NORTH AMERICA BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 77 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 78 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 79 NORTH AMERICA AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 80 NORTH AMERICA DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 81 NORTH AMERICA ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 82 NORTH AMERICA MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 83 NORTH AMERICA PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 84 NORTH AMERICA LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 85 NORTH AMERICA BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 86 NORTH AMERICA INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 87 NORTH AMERICA FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 88 NORTH AMERICA CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 89 NORTH AMERICA MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 90 NORTH AMERICA LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 91 NORTH AMERICA SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 92 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 93 NORTH AMERICA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 94 NORTH AMERICA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 95 NORTH AMERICA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 96 NORTH AMERICA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 97 NORTH AMERICA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 98 NORTH AMERICA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 99 NORTH AMERICA KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 100 NORTH AMERICA KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 101 NORTH AMERICA KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 102 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 103 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 104 NORTH AMERICA SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 105 NORTH AMERICA DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 106 NORTH AMERICA PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 107 NORTH AMERICA RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 108 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 109 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 110 U.S. NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 111 U.S. IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 112 U.S. BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 113 U.S. BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 114 U.S. NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 115 U.S. NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 116 U.S. AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 117 U.S. DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 118 U.S. ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 119 U.S. MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 120 U.S. PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 121 U.S. LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 122 U.S. BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 123 U.S. INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 124 U.S. FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 125 U.S. CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 126 U.S. MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 127 U.S. LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 128 U.S. SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 129 U.S. NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 130 U.S. INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 131 U.S. INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 132 U.S. INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 133 U.S. PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 134 U.S. PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 135 U.S. PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 136 U.S. KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 137 U.S. KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 138 U.S. KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 139 U.S. NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 140 U.S. NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 141 U.S. SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 142 U.S. DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 143 U.S. PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 144 U.S. RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 145 U.S. NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 146 U.S. NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 147 CANADA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 148 CANADA IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 149 CANADA BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 150 CANADA BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 151 CANADA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 152 CANADA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 153 CANADA AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 154 CANADA DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 155 CANADA ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 156 CANADA MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 157 CANADA PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 158 CANADA LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 159 CANADA BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 160 CANADA INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 161 CANADA FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 162 CANADA CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 163 CANADA MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 164 CANADA LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 165 CANADA SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 166 CANADA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 167 CANADA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 168 CANADA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 169 CANADA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 170 CANADA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 171 CANADA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 172 CANADA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 173 CANADA KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 174 CANADA KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 175 CANADA KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 176 CANADA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 177 CANADA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 178 CANADA SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 179 CANADA DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 180 CANADA PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 181 CANADA RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 182 CANADA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 183 CANADA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 184 MEXICO NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 185 MEXICO IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 186 MEXICO BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 187 MEXICO BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 188 MEXICO NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 189 MEXICO NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 190 MEXICO AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 191 MEXICO DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 192 MEXICO ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 193 MEXICO MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 194 MEXICO PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 195 MEXICO LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 196 MEXICO BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 197 MEXICO INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 198 MEXICO FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 199 MEXICO CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 200 MEXICO MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 201 MEXICO LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 202 MEXICO SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 203 MEXICO NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 204 MEXICO INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 205 MEXICO INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 206 MEXICO INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 207 MEXICO PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 208 MEXICO PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 209 MEXICO PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 210 MEXICO KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 211 MEXICO KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 212 MEXICO KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 213 MEXICO NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 214 MEXICO NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 215 MEXICO SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 216 MEXICO DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 217 MEXICO PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 218 MEXICO RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 219 MEXICO NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 220 MEXICO NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
图片列表
FIGURE 1 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: MULTIVARIATE MODELLING
FIGURE 7 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 10 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 12 THE INCREASING PREVALENCE OF NON-HODGKIN LYMPHOMA AND INCREASED RESEARCH & DEVELOPMENT IN NON-HODGKIN LYMPHOMA DIAGNOSTICS ARE DRIVING THE NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET IN THE FORECAST PERIOD OF 2023 TO 2030
FIGURE 13 REAGENTS & CONSUMABLES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET IN 2021 & 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET
FIGURE 15 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TEST TYPE, 2022
FIGURE 16 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TEST TYPE, 2023-2030 (USD MILLION)
FIGURE 17 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TEST TYPE, CAGR (2023-2030)
FIGURE 18 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TEST TYPE, LIFELINE CURVE
FIGURE 19 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TUMOR TYPE, 2022
FIGURE 20 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TUMOR TYPE, 2023-2030 (USD MILLION)
FIGURE 21 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TUMOR TYPE, CAGR (2023-2030)
FIGURE 22 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TUMOR TYPE, LIFELINE CURVE
FIGURE 23 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY APPLICATION, 2022
FIGURE 24 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY APPLICATION, 2023-2030 (USD MILLION)
FIGURE 25 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY APPLICATION, CAGR (2023-2030)
FIGURE 26 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 27 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY CANCER STAGE, 2022
FIGURE 28 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY CANCER STAGE, 2023-2030 (USD MILLION)
FIGURE 29 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY CANCER STAGE, CAGR (2023-2030)
FIGURE 30 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY CANCER STAGE, LIFELINE CURVE
FIGURE 31 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TECHNOLOGY, 2022
FIGURE 32 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION)
FIGURE 33 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TECHNOLOGY, CAGR (2023-2030)
FIGURE 34 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 35 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY PRODUCT, 2022
FIGURE 36 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY PRODUCT, 2023-2030 (USD MILLION)
FIGURE 37 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY PRODUCT, CAGR (2023-2030)
FIGURE 38 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 39 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY END USER, 2022
FIGURE 40 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 41 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY END USER, CAGR (2023-2030)
FIGURE 42 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY END USER, LIFELINE CURVE
FIGURE 43 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 44 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 45 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 46 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 47 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 48 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 49 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 50 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 51 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: TEST TYPE (2023-2030)
FIGURE 52 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
